Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Reviva Pharmaceuticals Holdings, Inc. RVPH

Healthcare Biotechnology
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug... see more

Recent & Breaking News (NDAQ:RVPH)

Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

GlobeNewswire May 4, 2023

Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

GlobeNewswire May 1, 2023

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

GlobeNewswire April 25, 2023

Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

GlobeNewswire April 20, 2023

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire April 19, 2023

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

GlobeNewswire March 30, 2023

Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

GlobeNewswire March 7, 2023

Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference

GlobeNewswire January 31, 2023

RedChip CEO Dave Gentry Invited to Join Forbes Business Council

Accesswire January 25, 2023

Reviva Pharmaceuticals Announces Letter to Shareholders

GlobeNewswire January 4, 2023

Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

GlobeNewswire December 15, 2022

Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208

GlobeNewswire November 21, 2022

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewswire November 14, 2022

Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

GlobeNewswire October 31, 2022

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire October 13, 2022

Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference

GlobeNewswire September 26, 2022

Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire September 6, 2022

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewswire August 15, 2022

Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

GlobeNewswire July 27, 2022